编者按：研究表明慢性淋巴细胞白血病（CLL）中激酶突变较为少见，因此靶向作用于信号途径的激酶抑制剂在B细胞进展中至为重要，尤其是靶向作用于B细胞受体(BCR)的相关已经引起了临床显著疗效。在本届ASCO年会上，美国俄亥俄州立大学医学中心Jeffrey A. Jones教授受邀做了关于回顾靶向治疗CLL的激酶抑制剂的临床进展的专题报告。会后，《肿瘤瞭望》对Jones教授进行了专访。

　　Oncology Frontier: Abstract Richter syndrome (RS) or Richter transformation is the development of secondary aggressive. What progress has been made in understanding the genetic events which relate to progression of CLL or transformation into RS?

　　《肿瘤瞭望》：Richter综合征或者Richter转变是在慢性淋巴细胞白血病/小淋巴细胞淋巴瘤的背景中，继发的侵袭性淋巴瘤。对该转变的基因改变研究有无最新进展？

 

　　Dr Jones: In general， the mechanism by which CLL transforms to high-grade lymphoma， Richter transformation， is not clear. The specific mechanism has not been elucidated. But who are the patients who are at greatest risk? This is the same group of patients who are at higher risk of relapsed and refractory CLL. We know there is an association between IGH mutation status and cytogenetics particularly with deletion 17p， so these patients are over-represented in the group that develop Richter transformation.

　　Jones教授：总体来说，CLL转化成高级别的淋巴瘤、Richter转化的机制并不清楚。IGH突变、del（17p）的患者是上述转化的高危人群。

 

上一页  [1]  [2]  [3]  [4]  下一页

评论发言